Related Experiment Video

Updated: May 28, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

The anti-inflammatory drug colchicine lacks efficacy in hidradenitis suppurativa

H H van der Zee1, E P Prens

  • 1Departmentof Dermatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands. h.vanderzee@erasmusmc.nl

Dermatology (Basel, Switzerland)
|October 15, 2011
PubMed

Insights

Colchicine did not improve hidradenitis suppurativa (HS) severity in a pilot study. The drug, while effective for other inflammatory conditions, showed no significant benefit for HS patients and caused side effects in some.

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition with limited effective treatments.
  • Emerging research highlights the role of inflammasome activation and IL-1β in HS pathogenesis.
  • Colchicine's known efficacy in other IL-1β-mediated inflammatory diseases suggests potential therapeutic value for HS.

Purpose of the Study:

  • To evaluate the efficacy of colchicine as a treatment for hidradenitis suppurativa.
  • To explore a potential new therapeutic avenue for this debilitating skin disease.

Main Methods:

  • An open-label, prospective pilot study was conducted.
  • Eight patients with hidradenitis suppurativa received oral colchicine at a dosage of 0.5 mg twice daily for up to four months.
  • Physician global assessment was used to measure treatment efficacy.

Main Results:

  • Colchicine treatment did not lead to clinically significant improvements in HS disease severity.
  • Common colchicine side effects, including nausea and diarrhea, were reported by three patients.
  • The study did not demonstrate a therapeutic benefit of colchicine for HS.

Conclusions:

  • The tested dosage regimen of colchicine is ineffective in ameliorating hidradenitis suppurativa severity.
  • Further research with different dosing or in specific patient subgroups may be warranted, but current evidence does not support its use.
  • Colchicine is not a viable treatment option for HS based on this pilot study.
Abstract

More Related Videos

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...